EPISODE · Dec 12, 2022 · 42 MIN
Biomarkers in IO: Challenges and Putative Benefits of Multi-omics Technologies
from PharmaTalkRadio · host Conference Forum
Evaluating single cell omics to understand the heterogeneity in immune and tumor cellsMulti-omic biomarkers for patient selection in solid tumor IO: is there a path to more personalized therapy?In an era of ‘targeted’ therapies against cell-intrinsic mechanisms (e.g. PARP, NTRK, BRAF) and surface molecules (Nectin-4, HER2), is there a path forward for pan-tumor biomarkers, or is multi-tumor more likely to be the dominant development mechanism? Moderated by: Theresa LaVallee, PhD, VP, Translational Medicine and Regulatory Affairs, Parker Institute for Cancer Immunotherapy Panelists: Jared Lunceford, PhD, Distinguished Scientist, Biostatistics and Research Decision Sciences, Merck Research LaboratoriesAngel A Rodriguez, MD, Oncology Medical Director, NateraSamik Upadhaya, PhD, Research Analyst, Anna-Maria Kellen Clinical Accelerator and Venture Fund, Cancer Research Institute (CRI) Learn more about the IO360° Summit at www.io360summit.com
What this episode covers
Evaluating single cell omics to understand the heterogeneity in immune and tumor cellsMulti-omic biomarkers for patient selection in solid tumor IO: is there a path to more personalized therapy?In an era of ‘targeted’ therapies against cell-intrinsic mechanisms (e.g. PARP, NTRK, BRAF) and surface molecules (Nectin-4, HER2), is there a path forward for pan-tumor biomarkers, or is multi-tumor more likely to be the dominant development mechanism? Moderated by: Theresa LaVallee, PhD, VP, Translational Medicine and Regulatory Affairs, Parker Institute for Cancer Immunotherapy Panelists: Jared Lunceford, PhD, Distinguished Scientist, Biostatistics and Research Decision Sciences, Merck Research LaboratoriesAngel A Rodriguez, MD, Oncology Medical Director, NateraSamik Upadhaya, PhD, Research Analyst, Anna-Maria Kellen Clinical Accelerator and Venture Fund, Cancer Research Institute (CRI) Learn more about the IO360° Summit at www.io360summit.com
NOW PLAYING
Biomarkers in IO: Challenges and Putative Benefits of Multi-omics Technologies
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.